TB-500 (Thymosin Beta-4 Fragment): Research, Mechanism & Current Evidence

What is TB-500?

TB-500 is a short synthetic peptide corresponding to the active region of thymosin beta-4, a naturally occurring protein of 43 amino acids found in most human cells. TB-500 reproduces roughly seven of those amino acids — the part that binds actin.

The two are frequently discussed as if interchangeable. They are not: the full protein has a broader set of documented activities than the fragment, and most published research uses the full protein.

Status: Not an approved medicine. Prohibited in sport by WADA.

What is TB-500 researched for?

Wound healing, muscle and tendon injury, corneal repair, and cardiac tissue after damage are the main areas.

A separate line of work concerns blood vessel formation and the migration of cells into injured tissue.

• Accelerated healing of muscle fibers with reduced recovery time and enhanced repair via cell migration and differentiation.
• Connective tissue repair with reduced scar formation and improved biomechanical properties of healing tissues.
• Enhanced dermal closure, improved angiogenesis, and reduced inflammation in acute and chronic scenarios.
• Faster recovery from intense training with reduced muscle soreness and improved tissue repair.
• Strengthened tissues through enhanced repair mechanisms may reduce injury risk.
• Improved muscle quality through enhanced regeneration and repair pathways.
• Protective effects against neuronal damage in various models.
• Preclinical evidence for improved outcomes in spinal injury models.
• Potential neuroprotective and regenerative effects on brain tissue.

How does TB-500 work?

Actin is the protein cells use to change shape and move. Thymosin beta-4 binds actin and controls how readily it assembles, which in turn affects how quickly cells can migrate into a wound.

In plain terms: repair depends on cells physically getting to the damaged area, and this family of peptides is studied because it influences that movement. Reported downstream effects include new blood vessel formation and reduced inflammatory signalling.

What does the research show?

The published evidence is predominantly laboratory and animal work. Full-length thymosin beta-4 reached clinical trials for chronic wounds and dry eye disease; the short TB-500 fragment has not been trialled in humans in the same way.

Where research reports faster healing, it is generally in rodent or cell-culture models rather than controlled human studies.

Limitations of the current evidence

Evidence for the fragment is routinely presented using data generated with the full-length protein. They are different molecules and the substitution is not justified by the literature.

No controlled human trial of TB-500 exists in any indication.

References

1. The regenerative peptide thymosin beta-4 accelerates the rate of dermal healing in preclinical animal models and in patients Treadwell, T., Kleinman, H.K., Crockford, D., Hardy, M.A., Guarnera, G.T., Goldstein, A.L. Annals of the New York Academy of

   Sciences · 2012

   In two Phase 2 clinical trials, thymosin beta-4 accelerated healing of chronic pressure ulcers and venous stasis ulcers by almost a month compared to placebo, with confirmed safety and tolerability.

   Controlled clinical trial

2. Development of thymosin beta4 for treatment of patients with ischemic heart disease

   Crockford D · Annals of the New York Academy of Sciences · 2007

   Synthetic thymosin beta-4 given intravenously was well tolerated with no dose-limiting toxicity; promotes cardiomyocyte migration and survival, and stimulates coronary vasculogenesis for cardiac ischemia treatment.

   PMID 17947592

3. Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse

   Spurney CF, Cha HJ, Sali A, et al. · PloS one · 2010

   Chronic thymosin beta-4 administration increased the number of regenerating skeletal muscle fibers in exercised dystrophin-deficient (mdx) mice, showing potential for Duchenne muscular dystrophy treatment.

   Animal study · PMID 20126456

4. Thymosin beta-4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial Sosne, G., Dunn, S.P., Kim, C. Cornea

   2015

   Phase 2 randomized trial in 9 severe dry eye patients showed RGN-259 (0.1% thymosin beta-4) eye drops achieved statistically significant improvements in both signs and symptoms, with effects lasting 28 days post-treatment.

   Controlled clinical trial

5. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta-4 in healthy Chinese volunteers

   Wang, X., et al. · Journal of Cellular and Molecular Medicine · 2021

   Phase I study in 54 healthy subjects with ascending doses (0.05-25.0 mcg/kg) demonstrated mild to moderate adverse events with no dose-limiting toxicities or serious adverse events.

   Controlled clinical trial

6. 0.1% RGN-259 (Thymosin beta-4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial Sosne, G., Kleinman, H.K., Springs, C., Gross, R.H., Sung, J., Kang

   S. International Journal of Molecular Sciences · 2022

   Phase III trial demonstrated thymosin beta-4 ophthalmic solution promotes corneal healing and improves comfort in neurotrophic keratopathy, advancing toward FDA approval.

   Controlled clinical trial

7. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients

   Treadwell T, Kleinman HK, Crockford D, et al. · Annals of the New York Academy of Sciences · 2012

   Early human study · PMID 23050815

8. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers

   Wang X, Liu L, Qi L, et al. · Journal of cellular and molecular medicine · 2021

   Controlled clinical trial · PMID 34346165

9. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial

   Sosne G, Dunn SP, Kim C · Cornea · 2015

   Controlled clinical trial · PMID 25826322

10. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial

    Sosne G, Kleinman HK, Springs C, et al. · International journal of molecular sciences · 2022

    Controlled clinical trial · PMID 36613994

Common questions